Imidazodiazepine compound

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10426784
APP PUB NO 20180185383A1
SERIAL NO

15737564

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds of formula (I) defined herein are useful as a dopamine D1 receptor positive allosteric modulators (D1 PAM) and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, schizophrenia negative symptom, CIAS, Parkinson's disease, Alzheimer's disease, Huntington's disease, depression, ADHD, drug dependency, or the like.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ASTELLAS PHARMA INC5-1 NIHONBASHI-HONCHO 2 -CHOME CHUO-KU TOKYO 103-8411 ?103-8411

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Imaizumi, Tomoyoshi Tokyo, JP 7 46
Kawakami, Shimpei Tokyo, JP 9 56
Kunikawa, Shigeki Tokyo, JP 8 99
Masuda, Naoyuki Tokyo, JP 20 246
Morita, Masataka Tokyo, JP 24 355
Yarimizu, Junko Tokyo, JP 1 2

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 1, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 1, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00